Turmerones / NO Cancer Research Results

TUR, Turmerones: Click to Expand ⟱
Features:

Turmerones — Turmerones are lipophilic volatile sesquiterpenes from turmeric rhizome oil, mainly ar-turmerone, α-turmerone, and β-turmerone. They are distinct from curcuminoids and should not be treated as curcumin synonyms. Formal classification: plant-derived volatile oil constituents / sesquiterpene ketones. Standard abbreviations include ATM or ar-T for aromatic turmerone, and α-TUR / β-TUR for α- and β-turmerone. Separate database product from whole turmeric or curcumin, because turmerones have different PK, BBB penetration, P-gp modulation, and apoptosis mechanisms from curcumin.

Primary mechanisms (ranked):

  1. ROS-linked mitochondrial and death-receptor apoptosis, especially reported for ar-turmerone in hepatocellular carcinoma and leukemia models.
  2. Growth suppression and programmed cell death in selected cancer cell lines, with strongest support in preclinical leukemia and hepatocellular carcinoma studies.
  3. Migration and invasion suppression in glioma models through cathepsin B and P27-related signaling.
  4. Inflammation and stress-pathway modulation, including NF-κB, JNK, p38 MAPK, COX-2, iNOS, cytokines, and MMP-related axes, mostly context-dependent.
  5. Curcumin bioavailability and transporter modulation, including altered Caco-2 transport and mixed P-gp effects depending on the turmerone isomer.

Bioavailability / PK relevance: Turmerones are more lipophilic than curcumin and are relevant as turmeric-oil constituents and as curcumin bioavailability modifiers. Reported animal PK suggests measurable systemic exposure, moderate oral bioavailability for major turmeric-oil constituents, and meaningful brain distribution. Human therapeutic PK for isolated turmerones remains insufficient.

In-vitro vs systemic exposure relevance: Many anticancer experiments use tens of μg/mL concentrations, which may exceed typical achievable free systemic exposure after ordinary turmeric intake. Turmeric oil or enriched turmerone formulations may increase exposure, but cancer-cell IC50 values should be treated as preclinical screening concentrations rather than clinically validated dosing targets.

Clinical evidence status: Preclinical. There is no strong cancer clinical-trial evidence for isolated turmerones. Human turmeric oil safety data and curcumin/turmeric-formulation trials do not establish turmerone-specific oncology efficacy. Recommended database status: add as a separate mechanistic/preclinical product, linked to turmeric oil and curcumin as related entries.

Turmerones Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial ROS apoptosis ↑ ROS, ↓ mitochondrial membrane potential, ↑ Bax, ↑ PUMA, ↑ cytochrome c release, ↑ caspase-9, ↑ caspase-3 Likely lower selectivity margin not fully established R/G Apoptosis induction Core ar-turmerone mechanism in hepatocellular carcinoma models; high concentration only; model-dependent
2 Death receptor apoptosis ↑ Fas, ↑ DR4, ↑ caspase-8, ↑ caspase-3 Insufficient direct comparison R/G Extrinsic apoptosis support Appears coupled to ROS and MAPK stress signaling rather than a fully independent primary trigger
3 JNK and ERK stress signaling ↑ JNK, ↑ ERK, ↑ pro-apoptotic signaling Context-dependent R/G Amplifies apoptosis Stress-kinase activation appears downstream of ROS in hepatocellular carcinoma models
4 Programmed cell death in leukemia ↑ DNA fragmentation, ↑ apoptotic morphology, ↓ viability Some selectivity reported versus selected non-target cells, but evidence remains limited G Cytotoxic apoptosis Older but relevant evidence supports ar-turmerone and related turmeric-oil constituents as apoptosis inducers in leukemia models
5 Glioma cathepsin B and P27 axis ↓ cathepsin B, ↓ P27 cleavage, ↓ proliferation, ↓ mobility Not well defined G Reduced proliferation and migration Potential CNS-oncology relevance because ar-turmerone is brain-penetrant; still preclinical
6 NF-κB inflammatory axis ↔/↓ NF-κB depending on model and stimulus ↓ NF-κB activation in inflammatory microglial models R/G Anti-inflammatory and context-dependent anticancer support curcuminoids suppress NF-κB more consistently than turmerones in some comparative studies
7 COX-2 iNOS MMP inflammatory mediators ↓ COX-2, ↓ MMP-related signaling (context-dependent) ↓ iNOS, ↓ COX-2, ↓ MMP-9 in activated microglia G Reduced inflammatory mediator output More relevant to inflammation, tumor microenvironment, and AD than direct tumor killing
8 P-gp and curcumin transport ↔ P-gp activity depending on isomer; ↑ curcumin cellular transport in Caco-2 model ↔ drug-transporter interaction risk R Bioavailability and drug-interaction modulation α-turmerone and ar-turmerone have different transporter effects; this is a key reason to keep turmerones separate from curcumin
9 Chemosensitization Possible ↑ intracellular exposure of co-administered compounds through transporter effects Possible altered exposure to normal tissues R/G Unproven adjunct potential Mechanistically plausible but not clinically established for oncology; not a strong chemosensitizer
10 Clinical Translation Constraint Preclinical activity often requires high μg/mL concentrations Oral oil safety appears better supported than isolated high-dose oncology use G Limits clinical confidence Major constraints are exposure, formulation, isomer composition, lack of isolated-turmerone cancer trials, and potential transporter-mediated interactions

P:0–30 min R:30 min–3 hr G:>3 hr
NO, Nitric Oxide: Click to Expand ⟱
Source:
Type:
Once the cancer has begun, NO seems to play a protumoral role rather than antitumoral one as the concentration required to cause tumor cell cytotoxicity cannot be achieved by cancer cells.
The mechanistic roles of nitric oxide (NO) during cancer progression have been important considerations since its discovery as an endogenously generated free radical. Nonetheless, the impacts of this signaling molecule can be seemingly contradictory, being both pro-and antitumorigenic, which complicates the development of cancer treatments based on the modulation of NO fluxes in tumors. At a fundamental level, low levels of NO drive oncogenic pathways, immunosuppression, metastasis, and angiogenesis, while higher levels lead to apoptosis and reduced hypoxia and also sensitize tumors to conventional therapies. However, clinical outcome depends on the type and stage of the tumor as well as the tumor microenvironment.
Nitric oxide is generated by three main nitric oxide synthase isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS).

– In many cancers, especially under inflammatory conditions, iNOS expression is upregulated. In contrast, eNOS levels may also be altered in cancers such as breast or prostate cancer.

• Expression Patterns in Tumors:
– Elevated iNOS expression is commonly observed in various tumor types (e.g., colon, breast, lung, and melanoma) and is often associated with an inflammatory microenvironment.

– Changes in eNOS and nNOS expression have also been reported and may contribute to angiogenesis and tumor blood flow regulation.
Scientific Papers found: Click to Expand⟱
6459- TUR,    Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis
- in-vivo, Nor, NA - in-vivo, Colon, NA
*NO?, eff↑, eff↑, AntiTum↑, *Inflam↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance ⓘ

eff↑, 2,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Angiogenesis & Vasculature ⓘ

NO?, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: NO, Nitric Oxide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:408  Target#:563  State#:%  Dir#:0
  wNotes=0  sortOrder:rid,rpid

 

Home Page